| 1.28 -0.01 (-0.78%) | 04-25 14:46 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.78 | 1-year : | 2.09 |
| Resists | First : | 1.53 | Second : | 1.78 |
| Pivot price | 1.28  |
|||
| Supports | First : | 1.11 | Second : | 0.92 |
| MAs | MA(5) : | 1.24  |
MA(20) : | 1.31 |
| MA(100) : | 1.55 |
MA(250) : | 1.47 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 46 |
D(3) : | 33.8 |
| RSI | RSI(14): 44.8 |
|||
| 52-week | High : | 2.56 | Low : | 0.83 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CYTH ] has closed below upper band by 48.3%. Bollinger Bands are 18% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.31 - 1.32 | 1.32 - 1.33 |
| Low: | 1.21 - 1.22 | 1.22 - 1.23 |
| Close: | 1.29 - 1.3 | 1.3 - 1.31 |
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.
Tue, 23 Apr 2024
Cyclo Therapeutics (NASDAQ:CYTH) Receives New Coverage from Analysts at Ascendiant Capital Markets - Defense World
Wed, 27 Mar 2024
Cyclo Therapeutics Insider Buyers Net US$310k Despite 10% Stock Decline - Simply Wall St
Fri, 15 Dec 2023
Healthcare Stocks Moving Friday: ICCT, VRCA, IMMX, CYTH, AADI, ALRN, CING, NEXI - InvestorsObserver
Wed, 08 Nov 2023
Healthcare Stocks Moving Wednesday: TNON, KRRO, VIRX, CYTH, ESTA, MRVI, PXMD, WRBY - InvestorsObserver
Thu, 21 Sep 2023
Applied Molecular stock falls on merger with Cyclo Therapeutics - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 0 (M) |
| Shares Float | 29 (M) |
| Held by Insiders | 1.587e+007 (%) |
| Held by Institutions | 39.4 (%) |
| Shares Short | 63 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.003e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 811.9 % |
| Return on Equity (ttm) | -143.6 % |
| Qtrly Rev. Growth | 1.08e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.03 |
| EBITDA (p.s.) | -0.68 |
| Qtrly Earnings Growth | -1.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 38.74 |
| Price to Cash Flow | -1.14 |
| Dividend | 0 |
| Forward Dividend | 45600 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|